Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 3/20 | 0.41 |
| ▸ | PRCP | P42785 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19511339 | 0.87 | HDAC4 (0.37) | ESR1ESR2NOS1PRCPSLC18A3 | |
| SCHEMBL19056869 | 0.79 | SLC40A1 (0.43) | NOS1MEN1KMT2ACYP3A4 | |
| SCHEMBL13306192 | 0.78 | ESR1 (0.51) | ESR1ESR2PRCPCYP11B2GRIN2B | |
| SCHEMBL5051433 | 0.78 | ESR1 (0.51) | ESR1ESR2PRCPCYP11B2GRIN2B | |
| SCHEMBL30124970 | 0.78 | ESR1 (0.51) | ESR1ESR2PRCPCYP11B2GRIN2B | |
| SCHEMBL13784817 | 0.78 | ESR1 (0.51) | ESR1ESR2PRCPCYP11B2GRIN2B | |
| SCHEMBL19056921 | 0.78 | NOS1 (0.36) | ESR1ESR2NOS1MEN1KMT2A | |
| SCHEMBL239601 | 0.78 | TOP1 (0.51) | ESR1ESR2NOS1PRCPCYP11B2 | |
| Hydrochloric Acid SCHEMBL30542604 | 0.77 | ESR1 (0.50) | ESR1ESR2PRCPCYP11B2GRIN2B | |
| SCHEMBL241233 | 0.76 | NPSR1 (0.34) | ESR1ESR2NOS1PRCPCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3239156-B1 | NOVEL GROUP 4 TRANSITION METAL COMPOUND AND USE OF SAME | HANWHA CHEMICAL CORP (KR) | 2023-03-01 | — | — | EP | disclosed |
| CN-107001500-B | Novel group 4 transition metal compound and use thereof | 韩华化学株式会社 | 2020-11-03 | — | — | CN | disclosed |
| US-10364302-B2 | Group 4 transition metal compound and use thereof | HANWHA CHEMICAL CORPORATION (KR) | 2019-07-30 | — | — | US | disclosed |
| US-20180002461-A1 | NOVEL GROUP 4 TRANSITION METAL COMPOUND AND USE THEREOF | HANWHA CHEMICAL CORPORATION (KR) | 2018-01-04 | — | — | US | disclosed |
| EP-3239156-A1 | NOVEL GROUP 4 TRANSITION METAL COMPOUND AND USE OF SAME | Hanwha Chemical Corporation (KR) | 2017-11-01 | — | — | EP | disclosed |
| CN-107001500-A | The 4th novel group transition metal compound and application thereof | 韩华化学株式会社 | 2017-08-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002461-A1 | NOVEL GROUP 4 TRANSITION METAL COMPOUND AND USE THEREOF | MORF4L1, TRPV4, TRPM4 | ESR1 2854/4885ESR2 4104/4885NOS1 534/4885 |
| US-10364302-B2 | Group 4 transition metal compound and use thereof | TRPM4, MORF4L1, TRPV4 | ESR1 3156/4885ESR2 4330/4885NOS1 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.